PRESTIGE CONSMR (PBH)
(Real Time Quote from BATS)
$70.14 USD
+0.01 (0.01%)
Updated Apr 25, 2024 03:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for Prestige Consumer Healthcare Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 1,128 | 1,087 | 943 | 963 |
Cost Of Goods | NA | 502 | 466 | 396 | 411 |
Gross Profit | NA | 625 | 621 | 547 | 552 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 648 | 291 | 250 | 261 |
Income After Depreciation & Amortization | 0 | -22 | 330 | 297 | 291 |
Non-Operating Income | NA | -2 | -3 | -11 | -3 |
Interest Expense | NA | 69 | 64 | 82 | 97 |
Pretax Income | NA | -94 | 262 | 204 | 191 |
Income Taxes | NA | -12 | 57 | 39 | 49 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -82 | 205 | 165 | 142 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -82 | 205 | 165 | 142 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 15 | 366 | 333 | 324 |
Depreciation & Amortization (Cash Flow) | NA | 37 | 36 | 35 | 33 |
Income After Depreciation & Amortization | 0 | -22 | 330 | 297 | 291 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 49.89 | 50.84 | 50.61 | 51.14 |
Diluted EPS Before Non-Recurring Items | NA | 4.21 | 4.06 | 3.24 | 2.96 |
Diluted Net EPS (GAAP) | NA | -1.65 | 4.04 | 3.25 | 2.78 |
Fiscal Year end for Prestige Consumer Healthcare Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 282.74 | 286.32 | 279.31 | 285.87 |
Cost Of Goods | NA | 124.80 | 126.30 | 124.64 | 132.11 |
Gross Profit | NA | 157.94 | 160.02 | 154.67 | 153.76 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 71.11 | 71.77 | 69.48 | 434.76 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 86.83 | 88.25 | 85.19 | -281.00 |
Non-Operating Income | NA | -0.68 | -0.23 | 1.24 | 0.45 |
Interest Expense | NA | 16.58 | 17.61 | 17.72 | 18.98 |
Pretax Income | NA | 69.58 | 70.42 | 68.71 | -299.52 |
Income Taxes | NA | 16.53 | 16.86 | 15.44 | -58.97 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 53.05 | 53.56 | 53.28 | -240.55 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 53.05 | 53.56 | 53.28 | -240.55 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 50.13 | 50.08 | 50.20 | 49.80 |
Diluted EPS Before Non-Recurring Items | NA | 1.06 | 1.07 | 1.06 | 1.07 |
Diluted Net EPS (GAAP) | NA | 1.06 | 1.07 | 1.06 | -4.80 |